

# Datasheet



Mouse mAb to **Alpha fetoprotein (AFP)**  
Clone **D10**  
Isotype **IgG1-κ**

## Source

A BALB/c mouse was immunized with alpha fetoprotein isolated from serum of hepatoma patients.  
Fusion partner: Sp2/0.

## Specifications


D10 has been characterized in the ISOBM TD-2 workshop and assigned by K. Nustad to group D of a cluster of 6 major epitopes of human alpha fetoprotein. Human alpha fetoprotein is an oncofetal protein of 70 kDa. It is expressed in fetal liver and is normally absent in healthy adult tissues. It is positive on all yolk sac tumors, on some other germ cell tumors and on hepatocellular carcinomas.

## Species reactivity

Positive: human.  
Negative: cow, dog, mouse, rat.

## Applications

D10 can be used for ELISA, the TD-2 workshop found D10 suitable for an AFP tumor marker test, both as solid phase as well as tracer antibody in combination with antibodies of epitope groups A and B. D10 is not suitable for IHC in paraffin sections, an appropriate antigen retrieval step has not been established.



**Figure 1:** Western blots of 2 AFP preparations stained with D10

ELISA	Flow cytometry	Frozen sections	Immunofluorescence	RIM
+	+	+	+	+

## Format

Produced in tissue culture, contains no host Ig. Antibodies are affinity purified and presented in PBS with 0,02% sodium azide.

Stored at 4°C-8°C, shelf life is at least 24 months after purchase.

## Dilution advice

- ELISA (solid phase: 0,1-100 µg/ml; tracer: 0,001-100 µg/ml for 30 min at RT).
- Flow cytometry (0,5-1,0 µg/million cells in 0,1 ml).
- Immunofluorescence (0,5-1,0 µg/ml).
- Immunohistology (1-2 µg/ml for 30 min at RT).
- RIM (solid phase 0,6 mg/ml, tracer: 0,5-1,2 mg/ml).

## Positive control

Hep-G2 cells, fetal liver or hepatocellular carcinoma.

# Datasheet



## References

- Tsung K., et al. *J. Immunol. Methods* **39**: 363-368 (1980).
- Michell B. et al. *Eur. J. Cancer Clin. Oncol.* **19**: 1239-1246 (1983).
- Yazova A.K. et al. *Immunol. Lett.* **25**: 325-330 (1990).
- Nustad K. Et al. *Tumor Biol* **19**: 293 -300 (1998).
- Yakimenko E.F. et al. *Tumor Biol* **19**: 301-309 (1998).